Santhera Pharmaceuticals Holding AG (SWX:SANN)
12.64
-0.14 (-1.10%)
At close: Jan 30, 2026
SWX:SANN Revenue
Santhera Pharmaceuticals Holding AG had revenue of 24.01M CHF in the half year ending June 30, 2025, with 509.62% growth. This brings the company's revenue in the last twelve months to 49.02M, down -56.85% year-over-year. In the year 2024, Santhera Pharmaceuticals Holding AG had annual revenue of 39.12M, down -62.17%.
Revenue (ttm)
49.02M
Revenue Growth
-56.85%
P/S Ratio
3.59
Revenue / Employee
620.46K
Employees
79
Market Cap
175.98M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 39.12M | -64.30M | -62.17% |
| Dec 31, 2023 | 103.41M | 95.94M | 1,283.84% |
| Dec 31, 2022 | 7.47M | 9.07M | - |
| Dec 31, 2021 | -1.60M | -16.60M | - |
| Dec 31, 2020 | 15.01M | -60.37M | -80.09% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Basilea Pharmaceutica AG | 236.21M |
| Idorsia | 232.51M |
| Newron Pharmaceuticals | 55.93M |
| BioVersys AG | 1.31M |
| Xlife Sciences AG | 839.38K |
| Molecular Partners AG | 681.00K |
| Addex Therapeutics | 158.54K |
Santhera Pharmaceuticals Holding AG News
- 16 days ago - Swissmedic Approves Santhera's AGAMREE For Duchenne Muscular Dystrophy - Nasdaq
- 3 months ago - Half Year 2025 Santhera Pharmaceuticals Holding AG Analyst Briefing Transcript - GuruFocus
- 4 months ago - Santhera Partners With Biomedica To Distribute Agamree In Russia - Nasdaq
- 4 months ago - Health Canada Approves Santhera's AGAMREE For Duchenne Muscular Dystrophy - Nasdaq
- 4 months ago - Santhera Pharmaceuticals Holding AG (SPHDF) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Santhera Pharmaceuticals Holding AG 2025 Q2 - Results - Earnings Call Presentation - Seeking Alpha
- 4 months ago - Santhera Pharma Stock Down On Wider H1 Loss; Is AGAMREE On Track? - Nasdaq
- 5 months ago - Santhera Enters into Agreement with Ikris Pharma Network for the Distribution of AGAMREE® (Vamorolone) in India - GlobeNewsWire